Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
108 hedge funds and large institutions have $1.56B invested in Mirati Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 26 closing their positions.
124% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $7.45M
108% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 26
106% more capital invested
Capital invested by funds: $757M → $1.56B (+$805M)
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
71% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 17
33% more funds holding
Funds holding: 81 → 108 (+27)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$41.7M |
| 2 |
BlackRock
New York
|
+$30.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.2M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$28.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$25.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$25.3M |
| 2 |
BC
Broadfin Capital
New York
|
-$16M |
| 3 |
Millennium Management
New York
|
-$14.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.5M |
| 5 |
PC
PointState Capital
New York
|
-$9.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
California Public Employees Retirement System
Sacramento,
California
| – | -$275K | -8,946 | Closed |
|
127
Marshall Wace
London,
United Kingdom
| – | -$268K | -8,740 | Closed |
|
|
SI
128
Sofinnova Investments
Menlo Park,
California
| – | -$267K | -8,688 | Closed |
|
|
CSS
129
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$193K | -6,302 | Closed |
|
130
Group One Trading
Chicago,
Illinois
| – | -$173K | -4,569 | Closed |
|
|
TRCT
131
Tower Research Capital (TRC)
New York
| – | -$70K | -2,265 | Closed |
|
132
Simplex Trading
Chicago,
Illinois
| – | -$60.5K | -1,602 | Closed |
|
|
FANJ
133
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$43K | -1,400 | Closed |
|
|
CG
134
Cutler Group
San Francisco,
California
| – | -$45.5K | -1,206 | Closed |
|
135
Acadian Asset Management
Boston,
Massachusetts
| – | -$17K | -547 | Closed |
|
MRTX Hedge Fund Activity: Q2 2018 in Review
108 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2018, worth a combined $1.56B — up 106% from $757M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new MRTX positions and 26 closed out — a net gain of 28 holders — while 29 added to existing stakes and 17 trimmed.
The largest buyer was Deerfield Management, adding an estimated $41.7M. The largest seller was Putnam Investments, cutting an estimated $25.3M.
- 108 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2018, up from 81 in Q1 2018.
- Funds reported $1.56B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2018, up 106% quarter-over-quarter.
- 54 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2018 and 26 closed out, a net change of +28 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2018 was Deerfield Management, an estimated $41.7M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2018 was Putnam Investments, an estimated $25.3M sold.
Based on aggregated 13F filings for Q2 2018.